Search

Your search keyword '"Satapathy, Sanjaya K."' showing total 330 results
Start Over Author "Satapathy, Sanjaya K." Search Limiters Full Text
330 results on '"Satapathy, Sanjaya K."'

2. Use of albumin infusion for cirrhosis-related complications: An international position statement

Author

Bai, Zhaohui, Méndez-Sánchez, Nahum, Romeiro, Fernando Gomes, Mancuso, Andrea, Philips, Cyriac Abby, Tacke, Frank, Basaranoglu, Metin, Primignani, Massimo, Ibrahim, Mostafa, Wong, Yu Jun, Nery, Filipe Gaio, Teschke, Rolf, Ferreira, Carlos Noronha, Muñoz, Alberto E., Pinyopornpanish, Kanokwan, Thevenot, Thierry, Singh, Shivaram Prasad, Mohanty, Arpan, Satapathy, Sanjaya K., Ridola, Lorenzo, Maruyama, Hitoshi, Cholongitas, Evangelos, Levi Sandri, Giovanni Battista, Yang, Li, Shalimar, Yang, Yongping, Villa, Erica, Krag, Aleksander, Wong, Florence, Jalan, Rajiv, O’Brien, Alastair, Bernardi, Mauro, and Qi, Xingshun

Published
2023
Full Text
View/download PDF

3. INASL–SAASL Consensus Statements on NAFLD Name Change to MAFLD

Author

Singh, Shivaram P., Duseja, Ajay, Mahtab, Mamun al, Anirvan, Prajna, Acharya, Subrat K., Akbar, Sheikh Mohammad Fazle, Butt, Amna S., Dassanayake, Anuradha, De, Arka, Dhakal, G.P., Hamid, Saeed, Madan, Kaushal, Panigrahi, Manas K., Rao, P.N., Saigal, Sanjiv, Satapathy, Sanjaya K., Shalimar, Shrestha, Ananta, Shukla, Akash, Sudhamshu, K.C., and Wijewantha, Hasitha

Published
2023
Full Text
View/download PDF

6. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma

Author

Singal, Amit G, Rich, Nicole E, Mehta, Neil, Branch, Andrea D, Pillai, Anjana, Hoteit, Maarouf, Volk, Michael, Odewole, Mobolaji, Scaglione, Steven, Guy, Jennifer, Said, Adnan, Feld, Jordan J, John, Binu V, Frenette, Catherine, Mantry, Parvez, Rangnekar, Amol S, Oloruntoba, Omobonike, Leise, Michael, Jou, Janice H, Bhamidimarri, Kalyan Ram, Kulik, Laura, Ioannou, George N, Huang, Annsa, Tran, Tram, Samant, Hrishikesh, Dhanasekaran, Renumathy, Duarte-Rojo, Andres, Salgia, Reena, Eswaran, Sheila, Jalal, Prasun, Flores, Avegail, Satapathy, Sanjaya K, Kagan, Sofia, Gopal, Purva, Wong, Robert, Parikh, Neehar D, and Murphy, Caitlin C

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Liver Disease, Chronic Liver Disease and Cirrhosis, Digestive Diseases, Cancer, Emerging Infectious Diseases, Clinical Research, Hepatitis, Rare Diseases, Prevention, Infectious Diseases, Liver Cancer, Hepatitis - C, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Infection, Good Health and Well Being, Aged, Antiviral Agents, Carcinoma, Hepatocellular, Female, Hepatitis C, Humans, Liver Neoplasms, Male, Middle Aged, North America, Protective Factors, Retrospective Studies, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, HCC, Survival, Neurosciences, Paediatrics and Reproductive Medicine, Gastroenterology & Hepatology, Clinical sciences, Nutrition and dietetics
Abstract

Background & aimsThere is controversy regarding the benefits of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection for patients with a history of hepatocellular carcinoma (HCC). We performed a multicenter cohort study to compare overall survival between patients with HCV infection treated with DAAs and patients who did not receive DAA treatment for their HCV infection after complete response to prior HCC therapy.MethodsWe conducted a retrospective cohort study of patients with HCV-related HCC who achieved a complete response to resection, local ablation, transarterial chemo- or radioembolization, or radiation therapy, from January 2013 through December 2017 at 31 health care systems throughout the United States and Canada. We used Cox proportional hazards regression to determine the association between receipt of DAA therapy, modeled as a time-varying covariate, and all-cause mortality, accounting for informative censoring and confounding using inverse probability weighting.ResultsOf 797 patients with HCV-related HCC, 383 (48.1%) received DAA therapy and 414 (51.9%) did not receive treatment for their HCV infection after complete response to prior HCC therapy. Among DAA-treated patients, 43 deaths occurred during 941 person-years of follow-up, compared with 103 deaths during 526.6 person-years of follow-up among patients who did not receive DAA therapy (crude rate ratio, 0.23; 95% confidence interval [CI], 0.16-0.33). In inverse probability-weighted analyses, DAA therapy was associated with a significant reduction in risk of death (hazard ratio, 0.54; 95% CI, 0.33-0.90). This association differed by sustained virologic response to DAA therapy; risk of death was reduced in patients with sustained virologic response to DAA therapy (hazard ratio, 0.29; 95% CI, 0.18-0.47), but not in patients without a sustained virologic response (hazard ratio, 1.13; 95% CI, 0.55-2.33).ConclusionsIn an analysis of nearly 800 patients with complete response to HCC treatment, DAA therapy was associated with a significant reduction in risk of death.

Published
2019

7. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study

Author

Singal, Amit G, Rich, Nicole E, Mehta, Neil, Branch, Andrea, Pillai, Anjana, Hoteit, Maarouf, Volk, Michael, Odewole, Mobolaji, Scaglione, Steven, Guy, Jennifer, Said, Adnan, Feld, Jordan J, John, Binu V, Frenette, Catherine, Mantry, Parvez, Rangnekar, Amol S, Oloruntoba, Omobonike, Leise, Michael, Jou, Janice H, Bhamidimarri, Kalyan Ram, Kulik, Laura, Tran, Tram, Samant, Hrishikesh, Dhanasekaran, Renumathy, Duarte-Rojo, Andres, Salgia, Reena, Eswaran, Sheila, Jalal, Prasun, Flores, Avegail, Satapathy, Sanjaya K, Wong, Robert, Huang, Annsa, Misra, Suresh, Schwartz, Myron, Mitrani, Robert, Nakka, Sasank, Noureddine, Wassim, Ho, Chanda, Konjeti, Venkata R, Dao, Alexander, Nelson, Kevin, Delarosa, Kelly, Rahim, Usman, Mavuram, Meher, Xie, Jesse J, Murphy, Caitlin C, and Parikh, Neehar D

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Liver Disease, Emerging Infectious Diseases, Digestive Diseases, Rare Diseases, Hepatitis - C, Hepatitis, Chronic Liver Disease and Cirrhosis, Clinical Research, Liver Cancer, Cancer, Infectious Diseases, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Aged, Antiviral Agents, Canada, Carcinoma, Hepatocellular, Female, Hepatitis C, Chronic, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, Retrospective Studies, Sustained Virologic Response, Time Factors, United States, Hepatitis C Virus, Recurrence, Direct-Acting Antiviral, Neurosciences, Paediatrics and Reproductive Medicine, Gastroenterology & Hepatology, Clinical sciences, Nutrition and dietetics
Abstract

Background & aimsThere is controversy over the effects of direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) infection on hepatocellular carcinoma (HCC) recurrence and tumor aggressiveness. We compared HCC recurrence patterns between DAA-treated and untreated HCV-infected patients who had achieved a complete response to HCC treatment in a North American cohort.MethodsWe conducted a retrospective cohort study of patients with HCV-related HCC with a complete response to resection, local ablation, transarterial chemo- or radioembolization, or radiation therapy from January 2013 through December 2017 at 31 health systems throughout the United States and Canada. Cox regression was used to examine the association between DAA therapy and time to recurrence after a complete response, with DAA therapy analyzed as a time-varying exposure. We also estimated the association between DAA therapy and risk of early HCC recurrence (defined as 365 days after complete response).ResultsOf 793 patients with HCV-associated HCC, 304 (38.3%) received DAA therapy and 489 (61.7%) were untreated. HCC recurred in 128 DAA-treated patients (42.1%; early recurrence in 52 patients) and 288 untreated patients (58.9%; early recurrence in 227 patients). DAA therapy was not associated with HCC recurrence (hazard ratio 0.90, 95% confidence interval 0.70-1.16) or early HCC recurrence (hazard ratio 0.96, 95% confidence interval 0.70-1.34) after we adjusted for study site, age, sex, Child-Pugh score, α-fetoprotein level, tumor burden, and HCC treatment modality. In DAA-treated and untreated patients, most recurrences were within the Milan criteria (74.2% vs 78.8%; P = .23). A larger proportion of DAA-treated than untreated patients received potentially curative HCC therapy for recurrent HCC (32.0% vs 24.6%) and achieved a complete or partial response (45.3% vs 41.0%) but this did not achieve statistical significance.ConclusionIn a large cohort of North American patients with complete response to HCC treatment, DAA therapy was not associated with increased overall or early HCC recurrence. HCC recurrence patterns, including treatment response, were similar in DAA-treated and untreated patients.

Published
2019

8. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.

Author

Tam, Edward, Luetkemeyer, Anne F, Mantry, Parvez S, Satapathy, Sanjaya K, Ghali, Peter, Kang, Minhee, Haubrich, Richard, Shen, Xianlin, Ni, Liyun, Camus, Gregory, Copans, Amanda, Rossaro, Lorenzo, Guyer, Bill, Brown, Robert S, and RESCUE and ACTG A5348 study investigators

Subjects
RESCUE and ACTG A5348 study investigators, Humans, Hepacivirus, Hepatitis C, Chronic, HIV Infections, Liver Cirrhosis, Headache, Fatigue, Benzimidazoles, Fluorenes, Ribavirin, Uridine Monophosphate, Antiviral Agents, Pregnancy, Adult, Aged, Middle Aged, Female, Male, Coinfection, Sofosbuvir, Sustained Virologic Response, HCV, HIV, ledipasvir, sofosbuvir, treatment-experienced, Gastroenterology & Hepatology, Clinical Sciences
Abstract

Background & aimsWe report data from two similarly designed studies that evaluated the efficacy, safety, and optimal duration of ledipasvir/sofosbuvir (LDV/SOF) ± ribavirin (RBV) for retreatment of chronic hepatitis C virus (HCV) in individuals who failed to achieve sustained virological response (SVR) with prior SOF-based, non-NS5A inhibitor-containing regimens.MethodsThe RESCUE study enrolled HCV mono-infected adults with genotype (GT) 1 or 4. Non-cirrhotic participants were randomized to 12 weeks of LDV/SOF or LDV/SOF + RBV. Compensated cirrhotic participants were randomized to LDV/SOF + RBV (12 weeks) or LDV/SOF (24 weeks). The AIDS Clinical Trials Group A5348 study randomized genotype 1 adults with HCV/HIV co-infection to LDV/SOF + RBV (12 weeks) or LDV/SOF (24 weeks). Both studies used SVR at 12 weeks post-treatment (SVR12) as the primary endpoint.ResultsIn the RESCUE study, 82 participants were randomized and treated, and all completed treatment. Overall, SVR12 was 88% (72/82); 81-100% in non-cirrhotic participants treated with LDV/SOF or LDV/SOF + RBV for 12 weeks and 80-92% in cirrhotic participants treated with LDV/SOF + RBV for 12 weeks or LDV/SOF for 24 weeks. Adverse events (AEs), mostly mild-to-moderate in severity, were experienced by 78% of participants, with headache and fatigue most frequently reported. One serious AE, not related to treatment, was observed. No premature discontinuations of study drug, or deaths occurred. In the A5348 study, seven participants were randomized (cirrhotic n = 1; GT1a n = 5) and all attained SVR12, with no serious AEs or premature discontinuations.ConclusionsIn this SOF-experienced, NS5A inhibitor-naïve population, which included participants with cirrhosis or HCV/HIV co-infection, high SVR12 rates were achieved.

Published
2018

10. An early experience on the effect of solid organ transplant status on hospitalized COVID-19 patients

Author

Nair, Vinay, Jandovitz, Nicholas, Hirsch, Jamie S., Abate, Mersema, Satapathy, Sanjaya K., Roth, Nitzan, Miyara, Santiago J., Guevara, Sara, Kressel, Adam M., Xiang, Alec, Wu, Grace, Butensky, Samuel D., Lin, David, Williams, Stephanie, Bhaskaran, Madhu C., Majure, David T., Grodstein, Elliot, Lau, Lawrence, Nair, Gayatri, Fahmy, Ahmed E., Winnick, Aaron, Breslin, Nadine, Berlinrut, Ilan, Molmenti, Christine, Becker, Lance B., Malhotra, Prashant, Gautam-Goyal, Pranisha, Lima, Brian, Maybaum, Simon, Shah, Samit K., Takegawa, Ryosuke, Hayashida, Kei, Shinozaki, Koichiro, Teperman, Lewis W., and Molmenti, Ernesto P.

Published
2021
Full Text
View/download PDF

12. Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma

Author

Rich, Nicole E., Yang, Ju Dong, Perumalswami, Ponni V., Alkhouri, Naim, Jackson, Whitney, Parikh, Neehar D., Mehta, Neil, Salgia, Reena, Duarte-Rojo, Andres, Kulik, Laura, Rakoski, Mina, Said, Adnan, Oloruntoba, Omobonike, Ioannou, George N., Hoteit, Maarouf A., Moon, Andrew M., Rangnekar, Amol S., Eswaran, Sheila L., Zheng, Elizabeth, Jou, Janice H., Hanje, James, Pillai, Anjana, Hernaez, Ruben, Wong, Robert, Scaglione, Steven, Samant, Hrishikesh, Kapuria, Devika, Chandna, Shaun, Rosenblatt, Russell, Ajmera, Veeral, Frenette, Catherine T., Satapathy, Sanjaya K., Mantry, Parvez, Jalal, Prasun, John, Binu V., Fix, Oren K., Leise, Michael, Lindenmeyer, Christina C., Flores, Avegail, Patel, Nayan, Jiang, Z. Gordon, Latt, Nyan, Dhanasekaran, Renumathy, Odewole, Mobolaji, Kagan, Sofia, Marrero, Jorge A., and Singal, Amit G.

Published
2020
Full Text
View/download PDF

13. Mechanistically based blood proteomic markers in the TGF-β pathway stratify risk of hepatocellular cancer in patients with cirrhosis

Author

Xiang, Xiyan, primary, Bhowmick, Krishanu, additional, Shetty, Kirti, additional, Ohshiro, Kazufumi, additional, Yang, Xiaochun, additional, Wong, Linda L., additional, Yu, Herbert, additional, Latham, Patricia S., additional, Satapathy, Sanjaya K., additional, Brennan, Christina, additional, Dima, Richard J., additional, Chambwe, Nyasha, additional, Sharifova, Gulru, additional, Cacaj, Fellanza, additional, John, Sahara, additional, Crawford, James M., additional, Huang, Hai, additional, Dasarathy, Srinivasan, additional, Krainer, Adrian R., additional, He, Aiwu R., additional, Amdur, Richard L., additional, and Mishra, Lopa, additional

Published
2024
Full Text
View/download PDF

14. Transplantation of kidneys from hepatitis C–infected donors to hepatitis C–negative recipients: Single center experience

Author

Molnar, Miklos Z., Nair, Satheesh, Cseprekal, Orsolya, Yazawa, Masahiko, Talwar, Manish, Balaraman, Vasanthi, Podila, Pradeep S.B., Mas, Valeria, Maluf, Daniel, Helmick, Ryan A., Campos, Luis, Nezakatgoo, Nosratollah, Eymard, Corey, Horton, Peter, Verma, Rajanshu, Jenkins, Ann Holbrook, Handley, Charlotte R., Snyder, Heather S., Cummings, Carolyn, Agbim, Uchenna A., Maliakkal, Benedict, Satapathy, Sanjaya K., and Eason, James D.

Published
2019
Full Text
View/download PDF

17. Association between alcohol-associated cirrhosis and inpatient complications among COVID-19 patients: A propensity-matched analysis from the United States

Author

Inayat, Faisal, primary, Ali, Hassam, additional, Patel, Pratik, additional, Dhillon, Rubaid, additional, Afzal, Arslan, additional, Rehman, Attiq Ur, additional, Afzal, Muhammad Sohaib, additional, Zulfiqar, Laraib, additional, Nawaz, Gul, additional, Goraya, Muhammad Hassan Naeem, additional, Subramanium, Subanandhini, additional, Agrawal, Saurabh, additional, and Satapathy, Sanjaya K, additional

Published
2023
Full Text
View/download PDF

19. Association of nonalcoholic fatty liver disease with acute cholangitis: a nationwide propensity-matched analysis from the United States

Author

Patel, Pratik, primary, Inayat, Faisal, additional, Ali, Hassam, additional, Afzal, Arslan, additional, Taj, Sobaan, additional, Rehman, Attiq Ur, additional, Hussain, Nadeem, additional, Ishtiaq, Rizwan, additional, Nawaz, Gul, additional, Afzal, Muhammad Sohaib, additional, Fatakhova, Karina, additional, and Satapathy, Sanjaya K., additional

Published
2023
Full Text
View/download PDF

27. Baseline Albumin-Bilirubin grade as a predictor of response and outcome of regorafenib therapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis

Author

Xu, Huilin, primary, Cao, Dedong, additional, Zhou, Dingjie, additional, Zhao, Nan, additional, Tang, Xixian, additional, Shelat, Vishalkumar G., additional, Samant, Hrishikesh, additional, Satapathy, Sanjaya K., additional, Tustumi, Francisco, additional, Aprile, Giuseppe, additional, He, Anbing, additional, Xu, Ximing, additional, and Ge, Wei, additional

Published
2023
Full Text
View/download PDF

29. Pathogenesis to management of hepatocellular carcinoma

Author

Da, Ben L., primary, He, Aiwu Ruth, additional, Shetty, Kirti, additional, Suchman, Kelly I., additional, Yu, Herbert, additional, Lau, Lawrence, additional, Wong, Linda L., additional, Rabiee, Atoosa, additional, Amdur, Richard L., additional, Crawford, James M., additional, Fox, Sharon S., additional, Grimaldi, Gregory M., additional, Shah, Priya K., additional, Weinstein, Jonathan, additional, Bernstein, David, additional, Satapathy, Sanjaya K., additional, Chambwe, Nyasha, additional, Xiang, Xiyan, additional, and Mishra, Lopa, additional

Published
2022
Full Text
View/download PDF

33. Outcomes after Liver Transplantation with Steatotic Grafts: Redefining Acceptable Cutoffs for Steatotic Grafts

Author

Jiang, Yu, primary, Da, Ben L, additional, Satiya, Jinendra, additional, Heda, Rajiv P, additional, Lau, Lawrence F, additional, Fahmy, Ahmed, additional, Winnick, Aaron, additional, Roth, Nitzan, additional, Grodstein, Elliot, additional, Thuluvath, Paul J, additional, Singal, Ashwani K, additional, Schiano, Thomas D, additional, Teperman, Lewis W, additional, and Satapathy, Sanjaya K, additional

Published
2022
Full Text
View/download PDF

35. Abstract 3379: Multi-cohort study shows HCC is associated with a relative regional reduction in TGFBR2 in liver biopsies from patients with cirrhosis

Author

Bhowmick, Krishanu, primary, Amdur, Richard, additional, Xiang, Xiyan, additional, Yu, Herbert, additional, Wong, Linda L., additional, Rao, Shuyun, additional, He, Aiwu R., additional, Amin, Karan, additional, Zaheer, Daewa, additional, Narayan, Raj K., additional, Satapathy, Sanjaya K., additional, Guha, Chandan, additional, Latham, Patricia S., additional, Shetty, Kirti, additional, Gough, Nancy R., additional, and Mishra, Lopa, additional

Published
2022
Full Text
View/download PDF

36. Using quantitative immunohistochemistry in patients at high risk for hepatocellular cancer

Author

Zaidi, Sobia, primary, Amdur, Richard, additional, Xiang, Xiyan, additional, Yu, Herbert, additional, Wong, Linda L., additional, Rao, Shuyun, additional, He, Aiwu R., additional, Amin, Karan, additional, Zaheer, Daewa, additional, Narayan, Raj K., additional, Satapathy, Sanjaya K., additional, Latham, Patricia S., additional, Shetty, Kirti, additional, Guha, Chandan, additional, Gough, Nancy R., additional, and Mishra, Lopa, additional

Published
2022
Full Text
View/download PDF

37. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis

Author

Akyıldız, Murat (ORCID 0000-0002-2080-7528 & YÖK ID 123080), Efe, Cumalı; Lammert, Craig; Taşçılar, Koray; Dhanasekaran, Renumathy; Ebik, Berat; Higuera-de la Tijera, Fatima; Çalışkan, Ali R.; Peralta, Mirta; Gerussi, Alessio; Massoumi, Hatef; Catana, Andreea M.; Purnak, Tuğrul; Rigamonti, Cristina; Aldana, Andres J. G.; Khakoo, Nidah; Nazal, Leyla; Frager, Shalom; Demir, Nurhan; Irak, Kader; Melekoğlu-Ellik, Zeynep; Kaçmaz, Hüseyin; Balaban, Yasemin; Atay, Kadri; Eren, Fatih; Alvares-da-Silva, Mario R.; Cristoferi, Laura; Urzua, Alvaro; Eskazan, Tugce; Magro, Bianca; Snijders, Romee; Barutçu, Sezgin; Lytvyak, Ellina; Zazueta, Godolfino M.; Demirezer-Bolat, Aylin; Aydın, Mesut; Heurgue-Berlot, Alexandra; De Martin, Eleonora; Ekin, Nazım; Yıldırım, Sumeyra; Yavuz, Ahmet; Bıyık, Murat; Narro, Graciela C.; Kıyıcı, Murat; Kahramanoğlu-Aksoy, Evrim; Vincent, Maria; Carr, Rotonya M.; Günsar, Fulya; Reyes, Eira C.; Harputluoğlu, Murat; Aloman, Costica; Gatselis, Nikolaos K.; Üstündağ, Yücel; Brahm, Javier; Vargas, Nataly C. E.; Güzelbulut, Fatih; Garcia, Sandro R.; Aguirre, Jonathan; Anders, Margarita; Ratusnu, Natalia; Hatemi, İbrahim; Mendizabal, Manuel; Floreani, Annarosa; Fagiuoli, Stefano; Silva, Marcelo; İdilman, Ramazan; Satapathy, Sanjaya K.; Silveira, Marina; Drenth, Joost P. H.; Dalekos, George N.; Assis, David N.; Bjornsson, Einar; Boyer, James L.; Yoshida, Eric M.; Invernizzi, Pietro; Levy, Cynthia; Montano-Loza, Aldo J.; Schiano, Thomas D.; Ridruejo, Ezequiel; Wahlin, Staffan, School of Medicine, Akyıldız, Murat (ORCID 0000-0002-2080-7528 & YÖK ID 123080), Efe, Cumalı; Lammert, Craig; Taşçılar, Koray; Dhanasekaran, Renumathy; Ebik, Berat; Higuera-de la Tijera, Fatima; Çalışkan, Ali R.; Peralta, Mirta; Gerussi, Alessio; Massoumi, Hatef; Catana, Andreea M.; Purnak, Tuğrul; Rigamonti, Cristina; Aldana, Andres J. G.; Khakoo, Nidah; Nazal, Leyla; Frager, Shalom; Demir, Nurhan; Irak, Kader; Melekoğlu-Ellik, Zeynep; Kaçmaz, Hüseyin; Balaban, Yasemin; Atay, Kadri; Eren, Fatih; Alvares-da-Silva, Mario R.; Cristoferi, Laura; Urzua, Alvaro; Eskazan, Tugce; Magro, Bianca; Snijders, Romee; Barutçu, Sezgin; Lytvyak, Ellina; Zazueta, Godolfino M.; Demirezer-Bolat, Aylin; Aydın, Mesut; Heurgue-Berlot, Alexandra; De Martin, Eleonora; Ekin, Nazım; Yıldırım, Sumeyra; Yavuz, Ahmet; Bıyık, Murat; Narro, Graciela C.; Kıyıcı, Murat; Kahramanoğlu-Aksoy, Evrim; Vincent, Maria; Carr, Rotonya M.; Günsar, Fulya; Reyes, Eira C.; Harputluoğlu, Murat; Aloman, Costica; Gatselis, Nikolaos K.; Üstündağ, Yücel; Brahm, Javier; Vargas, Nataly C. E.; Güzelbulut, Fatih; Garcia, Sandro R.; Aguirre, Jonathan; Anders, Margarita; Ratusnu, Natalia; Hatemi, İbrahim; Mendizabal, Manuel; Floreani, Annarosa; Fagiuoli, Stefano; Silva, Marcelo; İdilman, Ramazan; Satapathy, Sanjaya K.; Silveira, Marina; Drenth, Joost P. H.; Dalekos, George N.; Assis, David N.; Bjornsson, Einar; Boyer, James L.; Yoshida, Eric M.; Invernizzi, Pietro; Levy, Cynthia; Montano-Loza, Aldo J.; Schiano, Thomas D.; Ridruejo, Ezequiel; Wahlin, Staffan, and School of Medicine

Abstract

Background: we investigated associations between baseline use of immunosuppressive drugs and severity of Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis (AIH). Patients and methods: data of AIH patients with laboratory confirmed COVID-19 were retrospectively collected from 15 countries. The outcomes of AIH patients who were on immunosuppression at the time of COVID-19 were compared to patients who were not on AIH medication. The clinical courses of COVID-19 were classified as (i)-no hospitalization, (ii)-hospitalization without oxygen supplementation, (iii)-hospitalization with oxygen supplementation by nasal cannula or mask, (iv)-intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v)-ICU admission with invasive mechanical ventilation or (vi)-death and analysed using ordinal logistic regression. Results: we included 254 AIH patients (79.5%, female) with a median age of 50 (range, 17-85) years. At the onset of COVID-19, 234 patients (92.1%) were on treatment with glucocorticoids (n = 156), thiopurines (n = 151), mycophenolate mofetil (n = 22) or tacrolimus (n = 16), alone or in combinations. Overall, 94 (37%) patients were hospitalized and 18 (7.1%) patients died. Use of systemic glucocorticoids (adjusted odds ratio [aOR] 4.73, 95% CI 1.12-25.89) and thiopurines (aOR 4.78, 95% CI 1.33-23.50) for AIH was associated with worse COVID-19 severity, after adjusting for age-sex, comorbidities and presence of cirrhosis. Baseline treatment with mycophenolate mofetil (aOR 3.56, 95% CI 0.76-20.56) and tacrolimus (aOR 4.09, 95% CI 0.69-27.00) were also associated with more severe COVID-19 courses in a smaller subset of treated patients. Conclusion: baseline treatment with systemic glucocorticoids or thiopurines prior to the onset of COVID-19 was significantly associated with COVID-19 severity in patients with AIH., Italian Ministry of University and Research (MIUR) Department of Excellence; Project PREMIA (PREcision MedIcine Approach: bringing biomarker research to clinic)

Published
2022

46. An evaluation of the reporting quality in clinical practice guidelines for hepatocellular carcinoma using the RIGHT checklist

Author

Chen, Haiyang, primary, Tao, Meng, additional, Li, Ding, additional, Han, Jing, additional, Cheng, Cheng, additional, Ma, Yanfang, additional, Wu, Yingxi, additional, Shelat, Vishal G., additional, Tustumi, Francisco, additional, Satapathy, Sanjaya K., additional, Kang, Koo Jeong, additional, and Wang, Qiming, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results